Treatment
Rilzabrutinib clinical trials
We’re tracking 6 recruiting studies that include Rilzabrutinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06984627RecruitingPhase 2
Study of Rilzabrutinib for Adults with Graves' Disease
This study tests an experimental pill called rilzabrutinib for people with Graves' disease, a condition where the immune system attacks the thyroid. It aims to see if the drug can help control the overactive thyroid and any related eye problems.
Calgary, AlbertaAges 18–75 - NCT07190196RecruitingPhase 3
Study of Rilzabrutinib for IgG4-related disease
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
Fontana, CaliforniaAges 18 years+ - NCT06500702RecruitingPhase 2
Study of three drugs for FSGS or minimal change disease
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
Birmingham, AlabamaAges 16–75 - NCT06975865RecruitingPhase 3
Rilzabrutinib for sickle-cell disease pain episodes
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
Birmingham, AlabamaAges 10–65 - NCT07007962RecruitingPhase 3
Oral pill for immune thrombocytopenia after first treatment fails
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
Clovis, CaliforniaAges 18 years+ - NCT07086976RecruitingPhase 3
Study of oral rilzabrutinib for warm autoimmune hemolytic anemia
This trial tests an oral medication (rilzabrutinib) against a placebo for people with warm autoimmune hemolytic anemia (wAIHA). It aims to see if the drug can help control the disease with fewer side effects than current treatments.
Phoenix, ArizonaAges 18 years+
What Rilzabrutinib is being studied for
Conditions with recruiting Rilzabrutinib studies.
Common questions
- Are there clinical trials studying Rilzabrutinib?
- Yes. Clin2 currently lists 6 recruiting studies that include Rilzabrutinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Rilzabrutinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Rilzabrutinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Rilzabrutinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.